Comparative Pharmacology
Head-to-head clinical analysis: BREYNA versus ORTHO NOVUM 7 7 7 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREYNA versus ORTHO NOVUM 7 7 7 21.
BREYNA vs ORTHO-NOVUM 7/7/7-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BREYNA is a contraceptive vaginal ring that releases ethinyl estradiol and etonogestrel. Etonogestrel is a progestogen that inhibits ovulation by suppressing gonadotropin release. Ethinyl estradiol enhances the contraceptive effect by stabilizing the endometrium and increasing cervical mucus viscosity.
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
1 mg subcutaneously twice daily
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
None Documented
None Documented
Terminal elimination half-life is 12 hours; in patients with moderate to severe renal impairment, half-life may be prolonged up to 24 hours, requiring dose adjustment
Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days.
Primarily renal excretion of unchanged drug (approximately 70%) and biliary/fecal elimination (approximately 30%)
Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive